Immunis is a clinical-stage biotechnology company at the forefront of regenerative and longevity medicine, developing health-focused therapeutics for age and immune-mediated muscle and metabolic diseases. The company’s investigational therapeutic, IMM01-STEM, is a novel stem cell-derived secretome containing a diverse array of naturally occurring factors known to regulate immune signaling and promote muscle regeneration. IMM01-STEM activates multiple cellular pathways to potentially counteract the biological deficits underlying muscle and metabolic decline with age. By improving physical function, supporting metabolic health, and enhancing quality of life into old age, IMM01-STEM represents a groundbreaking approach to regenerative health. There are currently no FDA-approved secretomes, making IMM01-STEM the first therapeutic of its kind and making Immunis a global leader in secretome research.